Serum sclerostin levels were positively correlated with fat mass and bone mineral density in Central South Chinese postmenopausal women

Clinical Endocrinology

Volumn 76, Issue 6, 2012, Pages 797-801

  Sheng, Zhifeng ^a,b   Tong, Dejun ^b   Ou, Yangna ^b   Zhang, Hongbin ^b   Zhang, Zhimin ^b   Li, Shuang ^b   Zhou, Jianlin ^a   Zhang, Jian ^a   Liao, Eryuan ^b  

^a HUNAN NORMAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SCLEROSTIN;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE MINERAL; CHINESE; CROSS-SECTIONAL STUDY; ENZYME IMMUNOASSAY; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOFT TISSUE;

ABSORPTIOMETRY, PHOTON; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BODY COMPOSITION; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKERS; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 84860128591     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04315.x     Document Type: Article

References (22)

1. Sheng, Z., Xu, K., Ou, Y., et al. (2011) Relationship of body composition with prevalence of osteoporosis in central south Chinese postmenopausal women. Clinical Endocrinology (Oxford), 74, 319-324.
2. Hill, T.P., Später, D., Taketo, M.M., et al. (2005) Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Developmental Cell, 8, 727-738.
3. Baron, R., &, Rawadi, G., (2007) Targeting the Wnt/b-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology, 148, 2635-2643.
4. Glass II, D.A., Bialek, P., Ahn, J.D., et al. (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell, 8, 751-764.
5. Poole, K.E., van Bezooijen, R.L., Loveridge, N., et al. (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Journal of the Federation of American Societies for Experimental Biology, 19, 1842-1844.
6. Li, X., Ominsky, M.S., Niu, Q.T., et al. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Journal of Bone and Mineral Research, 23, 860-869.
7. Winkler, D.G., Sutherland, M.K., Geoghegan, J.C., et al. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. The EMBO Journal, 22, 6267-6276.
8. Balemans, W., Ebeling, M., Patel, N., et al. (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Human Molecular Genetics, 10, 537-543.
9. Balemans, W., Patel, N., Ebeling, M., et al. (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. Journal of Medical Genetics, 39, 91-97.
10. van Bezooijen, R.L., Roelen, B.A., Visser, A., et al. (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. Journal of Experimental Medicine, 199, 805-814.
11. Padhi, D., Jang, G., Stouch, B., et al. (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of Bone and Mineral Research, 26, 19-26.
12. Polyzos, S.A., Anastasilakis, A.D., Bratengeier, C., et al. (2011) Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporosis International, 23, 1171-1176.
13. Petridou, E., Mantzoros, C.S., Belechri, M., et al. (2005) Neonatal leptin levels are strongly associated with female gender, birth length, IGF-I levels and formula feeding. Clinical Endocrinology (Oxford), 62, 366-371.
14. McNulty, M., Singh, R.J., Li, X., et al. (2011) Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. Journal of Clinical Endocrinology and Metabolism, 96, E1159-1162.
15. Mödder, U.I., Hoey, K.A., Amin, S., et al. (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. Journal of Bone and Mineral Research, 26, 373-379.
16. Gnudi, S., Sitta, E., &, Fiumi, N., (2007) Relationship between body composition and bone mineral density in women with and without osteoporosis: relative contribution of lean and fat mass. Journal of Bone and Mineral Metabolism, 25, 326-332.
17. Li, S., Wagner, R., Holm, K., et al. (2004) Relationship between soft tissue body composition and bone mass in perimenopausal women. Maturitas, 47, 99-105.
18. Mirza, F.S., Padhi, I.D., Raisz, L.G., et al. (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 95, 1991-1997.
19. Gaudio, A., Pennisi, P., Bratengeier, C., et al. (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. Journal of Clinical Endocrinology and Metabolism, 95, 2248-2253.
20. Tian, X., Setterberg, R.B., Li, X., et al. (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone, 47, 529-533.
21. Ardawi, M.S., Al-Kadi, H.A., Rouzi, A.A., et al. (2011) Determinants of serum sclerostin in healthy pre- and postmenopausal women. Journal of Bone and Mineral Research, 26, 2812-2822.
22. van Lierop, A.H., Witteveen, J.E., Hamdy, N.A., et al. (2010) Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. European Journal of Endocrinology, 163, 833-837.